Back to first-pass browser

First-pass extracted concept

mtDNA-targeted base editing

Candidate: concept label1 source documents4 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This strategy edits mitochondrial DNA directly and is presented as a major gene therapy modality for mitochondrial disease.

Source 1DOIPubMed

Resources required

The abstract emphasizes safe delivery, tissue-specific expression, and maintenance of long-term specificity and efficiency.

Source 1DOIPubMed

What problem it solves

It is presented as a promising route for correcting disorders caused by mtDNA mutations.

Source 1DOIPubMed

What it does not solve

The abstract states that mitochondrial physiology and current technical limitations still hinder clinical implementation.

Source 1DOIPubMed

Alternatives

The review contrasts this strategy with allotopic expression and mitochondrial-targeted nuclease cleavage.

Source 1DOIPubMed

Evidence Snippets

including the allotopic expression of mtDNA in the nucleus, mitochondrial-targeted nuclease cleavage, and mtDNA-targeted base editing
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1evidence maturitysupports2025Source 1DOIPubMed

The review discusses clinical efficacy for mtDNA allotopic expression and preclinical progress for other mitochondrial gene therapy strategies.

Claim 2implementation challengesupports2025Source 1DOIPubMed

Unique physiological features of mitochondria, including heteroplasmy and independent molecular transport mechanisms, create distinct challenges for clinical implementation of mitochondrial gene therapy strategies.

Claim 3strategy scopesupports2025Source 1DOIPubMed

Gene therapy strategies applicable to mitochondrial diseases include allotopic expression of mtDNA in the nucleus, mitochondrial-targeted nuclease cleavage, and mtDNA-targeted base editing.

Claim 4translation requirementsupports2025Source 1DOIPubMed

Clinical translation of mitochondrial gene therapy requires understanding heteroplasmy dynamics and phenotypes, safe delivery and tissue-specific expression of therapeutic elements, and long-term therapeutic specificity and efficiency.